[4]Müller V, Bachelot T, Curigliano G, et al. Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer. Cancer Treat Rev. Published online November 17, 2024. [5]Gori S, Puglisi F, Moroso S, et al. The HERBA Study: A Retrospective Multi-Insti...
上述研究成果以“DNA framework-controlled Poly(MOFs) as a visual platform for diagnosis of HER2-positive breast cancer”为题发表在Nano Today上(https://doi.org/10.1016/j.nantod.2023.102143),李根喜教授、殷咏梅教授以及赵婧教授为文章的共同通讯作者,我校生命科学学院2020级博士研究生梁齐志为文章的第一作者。
5. Gingras I, Gebhart G, De Azambuja E & Piccart-Gebhart M 2017 HER2positive breast cancer is lost in translation: time for patient-centered research. Nature Reviews: Clinical Oncology 14 669-681. 6. Li LT, Jiang ...
[14]Jerusalem G, Park YH, Hurvitz SA, et al. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discov. 2022 Oct 18:CD-22-0837. [15]Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan...
[1]https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html [2]https://www.cancer.org/cancer/types/breast-cancer/treatment/targeted-therapy-for-breast-cancer....
[6]Hou Y, Nitta H, Wei L, et al. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat. 2017;166(2):447-457. ...
Her2 positive breast cancer from optimal diagnosis to optimal treatmentCameronD.A.ingentaconnectEuropean Journal of Cancer Supplement
[2] Wu VS, Kanaya N, Lo C, et al. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? J Steroid Biochem Mol Biol. 2015 Sep;153:45-53. [3] Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in...
Recent series have shown that women with HER2-positive metastatic breast cancer receiving the drug trastuzumab develop brain metastases more frequently than this, but also that continuation of trastuzumab after diagnosis of brain metastases in such patients is associated with extended survival. Authors ...
HER2‐positive breast cancerT‐DM1trastuzumabtucatinibBackground Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)﹑ositive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous ...